Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stroke 2Prostatic Neoplasms 2Osteoporosis 2Neoplasms 2Kidney Diseases 2Hypertension 2Heart Failure 2Frailty 2Diabetes Mellitus 2Colorectal Neoplasms 2Cardiovascular Diseases 2Arthritis 2Weight Loss 1Rectal Neoplasms 1Obesity-Related Malignant Neoplasm 1Obesity 1Neoplasm Metastasis 1Motor Activity 1Lung Neoplasms 1Digestive System Carcinoma 1Colonic Neoplasms 1Chronic Disease 1Bone Diseases, Metabolic 1

Interventions

anamorelin 2Melatonin 2Megestrol Acetate 2TOPS 1Sugars 1Palonosetron 1Nutrition Assessment 1Mirtazapine 1Metformin 1Liraglutide 1Ibuprofen 1Flurandrenolone 1Exercise 1Exenatide 1Endoscopy, Digestive System 1Atenolol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Weight Loss × Nutrition Assessment × Clear all
NCT03035409 2025-11-10

Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
129 enrolled 11 charts

Neoplasm Metastasis, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡